Arcadia Biosciences Inc
$ 1.86
0.00%
24 Feb - close price
- Market Cap 4,068,900 USD
- Current Price $ 1.86
- High / Low $ 1.92 / 1.76
- Stock P/E N/A
- Book Value 3.98
- EPS -3.69
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -0.65 %
- 52 Week High 5.72
- 52 Week Low 1.54
About
Arcadia Biosciences, Inc. is dedicated to developing various crop productivity traits primarily in hemp, wheat, and soybeans. The company is headquartered in Davis, California.
Analyst Target Price
$12.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-14 | 2025-05-07 | 2025-03-26 | 2024-11-12 | 2024-08-13 | 2024-05-22 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | 0.62 | -3.26 | 1.9 | -2.99 | -0.87 | 0.78 | -1.78 | -2.52 | -1.44 | -2.65 | -10.86 | -6.29 |
| Estimated EPS | -0.94 | -1.22 | -0.98 | -0.89 | -0.81 | 1.55 | -2.21 | -2.58 | -3.19 | -4.8 | -6.85 | -6.8 |
| Surprise | 1.56 | -2.04 | 2.88 | -2.1 | -0.06 | -0.77 | 0.43 | 0.06 | 1.75 | 2.15 | -4.01 | 0.51 |
| Surprise Percentage | 165.9574% | -167.2131% | 293.8776% | -235.9551% | -7.4074% | -49.6774% | 19.457% | 2.3256% | 54.8589% | 44.7917% | -58.5401% | 7.5% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RKDA
2026-02-17 01:18:40
This article provides a financial snapshot for Arcadia Biosciences, Inc. (FWB:17D), focusing on its cash per share value. The content is presented within the context of the Frankfurt Stock Exchange, indicating that the market was closed at the time of publication. It details the company's financial overview, with data sourced from ICE Data Services and FactSet Research Systems Inc.
2026-02-06 22:01:31
Arcadia Biosciences (RKDA) announced the resignations of two board directors, Albert D. Bolles, Ph.D., and Deborah Carosella, effective February 4, 2026. The company stated the resignations were not due to disputes and both former directors will remain available in an advisory capacity. TipRanks' AI Analyst, Spark, rates RKDA as Neutral, citing weak financial performance and bearish technicals, despite a debt-free balance sheet.
2026-01-14 10:58:13
Arcadia Biosciences has completed financing transactions to raise approximately $2.1 million. The company signed inducement offer letters with investors on January 9, 2026, leading to the exercise of existing options and the issuance of new ones. H.C. Wainwright acted as the exclusive placement agent for these transactions, which closed on January 12, 2026, with proceeds designated for working capital and general corporate purposes.
2026-01-13 12:58:13
Arcadia Biosciences secured approximately $2.1 million in gross proceeds by inducing certain investors to exercise existing preferred investment options at a reduced price of $2.575 per share, down from $9.00. In exchange, the company issued new unregistered preferred investment options and placement agent options, which allow for the purchase of additional shares at lower prices. The company plans to use the proceeds for working capital and general corporate purposes, while agreeing to restrictions on future equity issuances for certain periods.
2026-01-13 12:57:52
Arcadia Biosciences, Inc. (Nasdaq: RKDA) announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options, generating approximately $2.1 million in gross proceeds. This exercise involves purchasing shares originally issued between December 2020 and March 2023, at a reduced exercise price of $2.575 per share from an original $9.00. The company plans to use the net proceeds for working capital and general corporate purposes.
2026-01-12 13:29:32
Arcadia Biosciences, Inc. (RKDA) announced the exercise of outstanding preferred investment options, generating approximately $2.1 million in gross proceeds. The original options were issued between December 2020 and March 2023, and the exercise price was reduced from $9.00 to $2.575 per share. In exchange, Arcadia will issue new unregistered preferred investment options to purchase up to 1,617,190 shares of common stock, which will be exercisable at $2.325 per share.
